Stock DERM JOURNEY MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
5.66 USD -0.35% Intraday chart for Journey Medical Corporation +8.64% -1.74%
Jul. 11 Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors CI
May. 13 Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
AQ
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
CI
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
AQ
Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024
Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Posts Q1 Revenue $13M, vs. Street Est of $14.1M
MT
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
AQ
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
AQ
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
AQ
Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer
CI
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
AQ
Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
AQ
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
CI
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DERM Stock
  4. News Journey Medical Corporation